Targeting the Angiotensin Pathway in the Treatment of Cutaneous Fibrosis: A Systematic Review

Trenton Greif; Mouaz Alsawas; Alexander T. Reid; Vincent Liu; Larry Prokop; M.H. Murad; Jennifer G. Powers

doi:10.1016/j.xjidi.2023.100231

Back

Targeting the Angiotensin Pathway in the Treatment of Cutaneous Fibrosis: A Systematic Review

Journal article

Open access

Peer reviewed

Targeting the Angiotensin Pathway in the Treatment of Cutaneous Fibrosis: A Systematic Review

Trenton Greif, Mouaz Alsawas, Alexander T. Reid, Vincent Liu, Larry Prokop, M.H. Murad and Jennifer G. Powers

JID innovations, Vol.3(6), 100231

11/2023

DOI: 10.1016/j.xjidi.2023.100231

PMCID: PMC10568560

PMID: 37840767

Files and links (1)

url

https://doi.org/10.1016/j.xjidi.2023.100231View

Published (Version of record) Open Access

Abstract

Acting on the renin-angiotensin-aldosterone system (RAAS), angiotensin converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) are mechanisms of some of the most prescribed medications in the world. In addition to their routine use for the treatment of hypertension, such agents have gained attention for their influence of the angiotensin receptor pathway on fibrotic skin disorders including scars and keloids. In order to evaluate the current level of evidence supporting use of these agents, a systematic review related to ACE-Is/ARBs and cutaneous scarring was conducted. We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus from database inception through January 26th, 2022. Two independent reviewers identified eligible studies for inclusion and extracted data. Data were insufficient for meta-analysis and are presented narratively. Out of 461 citations identified, seven studies were included (199 patients). The studies included two randomized clinical trials, one comparative observation study, and four case reports. All the included studies reported statistically significant improvement in cutaneous scarring with patients using ACE-Is/ARBs compared to placebo/control using various outcome measures such as scar size and scar scales. Much of the literature on this subject to date, however, is limited by study design.

Details

Title: Subtitle: Targeting the Angiotensin Pathway in the Treatment of Cutaneous Fibrosis: A Systematic Review
Creators: Trenton Greif
Mouaz Alsawas
Alexander T. Reid
Vincent Liu
Larry Prokop
M.H. Murad
Jennifer G. Powers
Resource Type: Journal article
Publication Details: JID innovations, Vol.3(6), 100231
DOI: 10.1016/j.xjidi.2023.100231
PMID: 37840767
PMCID: PMC10568560
NLM abbreviation: JID Innov
ISSN: 2667-0267
eISSN: 2667-0267
Language: English
Electronic publication date: 09/2023
Date published: 11/2023
Academic Unit: Dermatology; Pathology
Record Identifier: 9984464516702771

Metrics

7 Record Views